The recent results obtained with the incretins analogues in individuals with a BMI at 27 and at least one obesity-related complication and those with a BMI > 30 are of great interest and may revolutionize the field of bariatric surgery in the foreseeable future [31]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.